[18F]FLT is superior to [18F]FDG for predicting early response to antiproliferative treatment in high-grade lymphoma in a dose-dependent manner

[1] Cheson BD(1999)Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group J Clin Oncol 17 1244-1837

[2] Horning SJ(1988)Residual abdominal masses in aggressive non-Hodgkin’s lymphoma after combination chemotherapy: significance and management J Clin Oncol 6 1832-578

[3] Coiffier B(2007)Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma J Clin Oncol 25 571-207

[4] Shipp MA(2005)FDG-PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls Radiographics 25 191-700

[5] Fisher RI(2004)Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model J Nucl Med 45 695-1762

[6] Surbone A(1998)Carbon-11-thymidine and FDG to measure therapy response J Nucl Med 39 1757-1336

[7] Longo DL(1998)Imaging proliferation in vivo with [F-18]FLT and positron emission tomography Nat Med 4 1334-263

[8] DeVita VT(2005)The uptake of 3′-deoxy-3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels Eur J Nucl Med Mol Imaging 32 257-25

[9] Ihde DC(1994)Properties and levels of deoxynucleoside kinases in normal and tumor cells; implications for chemotherapy Adv Enzyme Regul 34 13-1181

[10] Duffey PL(2002)Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3′-[(18)F]fluoro-3′-deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines Eur J Nucl Med Mol Imaging 29 1174-1217

[1] Cheson BD(1999)Report of an international workshop to standardize response criteria for non-Hodgkin’s lymphomas. NCI Sponsored International Working Group J Clin Oncol 17 1244-1837

[2] Horning SJ(1988)Residual abdominal masses in aggressive non-Hodgkin’s lymphoma after combination chemotherapy: significance and management J Clin Oncol 6 1832-578

[3] Coiffier B(2007)Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma J Clin Oncol 25 571-207

[4] Shipp MA(2005)FDG-PET in the evaluation of treatment for lymphoma: clinical usefulness and pitfalls Radiographics 25 191-700

[5] Fisher RI(2004)Selectivity of 18F-FLT and 18F-FDG for differentiating tumor from inflammation in a rodent model J Nucl Med 45 695-1762

[6] Surbone A(1998)Carbon-11-thymidine and FDG to measure therapy response J Nucl Med 39 1757-1336

[7] Longo DL(1998)Imaging proliferation in vivo with [F-18]FLT and positron emission tomography Nat Med 4 1334-263

[8] DeVita VT(2005)The uptake of 3′-deoxy-3′-[18F]fluorothymidine into L5178Y tumours in vivo is dependent on thymidine kinase 1 protein levels Eur J Nucl Med Mol Imaging 32 257-25

[9] Ihde DC(1994)Properties and levels of deoxynucleoside kinases in normal and tumor cells; implications for chemotherapy Adv Enzyme Regul 34 13-1181

[10] Duffey PL(2002)Evaluation of pyrimidine metabolising enzymes and in vitro uptake of 3′-[(18)F]fluoro-3′-deoxythymidine ([(18)F]FLT) in pancreatic cancer cell lines Eur J Nucl Med Mol Imaging 29 1174-1217